Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristian Reich

Showing results (171-180 of 265) with videos related to

Pageof 27
Sort By:
Journal of the American Academy of Dermatology|October 25, 2011
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasisAlexa B Kimball, Philippe Szapary, Ulrich Mrowietz, et al.
Archives of Dermatological Research|October 31, 2006
Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanomaRotraut Mössner, Nils Anders, Inke R König, et al.
The Journal of Investigative Dermatology|February 1, 2021
Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. SecukinumabHeena Mehta, Shunya Mashiko, Julianty Angsana, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|March 1, 2014
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyMark G Lebwohl, Hervé Bachelez, Jonathan Barker, et al.
Journal of the American Academy of Dermatology|September 25, 2016
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR studyAndrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, et al.
Dermatology and Therapy|August 8, 2020
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)Jean-Philippe Lacour, Anthony Bewley, Edward Hammond, et al.
The British Journal of Dermatology|September 16, 2023
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscapeJames G Krueger, John Frew, Gregor B E Jemec, et al.
Journal of the American Academy of Dermatology|May 17, 2016
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasisPeter C M van de Kerkhof, Christopher E M Griffiths, Kristian Reich, et al.
Pageof 27

Showing results (171-180 of 265) with videos related to

Sort By:
Pageof 27
Journal of the American Academy of Dermatology|October 25, 2011
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasisAlexa B Kimball, Philippe Szapary, Ulrich Mrowietz, et al.
Archives of Dermatological Research|October 31, 2006
Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanomaRotraut Mössner, Nils Anders, Inke R König, et al.
The Journal of Investigative Dermatology|February 1, 2021
Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. SecukinumabHeena Mehta, Shunya Mashiko, Julianty Angsana, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|March 1, 2014
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyMark G Lebwohl, Hervé Bachelez, Jonathan Barker, et al.
Journal of the American Academy of Dermatology|September 25, 2016
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR studyAndrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, et al.
Dermatology and Therapy|August 8, 2020
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)Jean-Philippe Lacour, Anthony Bewley, Edward Hammond, et al.
The British Journal of Dermatology|September 16, 2023
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscapeJames G Krueger, John Frew, Gregor B E Jemec, et al.
Journal of the American Academy of Dermatology|May 17, 2016
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasisPeter C M van de Kerkhof, Christopher E M Griffiths, Kristian Reich, et al.
Pageof 27